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Background/Aims: Microscopic colitis is characterized by 
chronic watery diarrhea with specific pathological changes that 
can be diagnosed by microscopic examination. We performed 
immunohistochemical analysis of proinflammatory cytokines 
to investigate the pathogenic mechanism of microscopic colitis. 
Methods: This study consisted of six patients with lymphocytic 
colitis, six patients with collagenous colitis, and six patients with 
functional diarrhea but normal pathology. We performed an 
immunohistochemical analysis of the colonic mucosal biopsies 
to assess the expression of cyclo-oxygenase-2, interleukin-17, 
nuclear factor-κB, interferon-γ, inducible nitric oxide synthase, 
and tumor necrosis factor-α. We compared the quantity score 
of immunohistochemical staining among the groups. Results: 
The microscopic colitis group showed significantly higher ex-
pression of cyclo-oxygenase-2, interleukin-17, nuclear factor-
κB, and interferon-γ compared with the control group. Cytokine 
expression was similar between collagenous colitis and lympho-
cytic colitis. However, the expression of cyclo-oxygenase-2 was 
higher in collagenous colitis. Conclusions: Proinflammatory 
cytokines, including interleukin-17 and interferon-γ, are highly 
expressed in microscopic colitis. The expression of cyclo-oxy-
genase-2 was higher in collagenous colitis than in lymphocytic 
colitis. This study is the first on interleukin-17 expression in 
microscopic colitis patients. (Gut Liver 2015;9:381-387)
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INTRODUCTION
Microscopic colitis (MC) is a chronic inflammatory bowel dis-
ease with unknown etiology characterized by chronic watery di-
arrhea without gross abnormalities on endoscopic examination.1 
The histological classification of MC reveals two distinct dis-
eases: collagenous colitis (CC) and lymphocytic colitis (LC). CC is 
defined by colonic intraepithelial lymphocytosis and increased 
numbers of inflammatory cells within the lamina propria, which 
develops a thickened subepithelial collagen band. Intraepithelial 
lymphocytosis is also evident in LC; however, there is no sub-
epithelial collagen band.2
The pathogenesis of MC remains unknown. Moreover, it is 
not clear whether CC and LC are the same disease entity. Some 
evidence suggests that MC occurs as a response to a luminal 
antigen, such as bile acid, toxins, colonic infections, and medi-
cations, including nonsteroidal anti-inflammatory drugs and 
proton pump inhibitors.3 These causative factors increase lumi-
nal permeability and subsequent inflammatory responses in the 
lamina propria.4,5
The cytokine profile of MC has not been fully evaluated. 
A few studies have investigated the cytokine profile of MC, 
including T helper cell type 1 mucosal cytokine, interferon-γ 
(IFN-γ), nuclear factor-κB (NF-κB), cyclo-oxygenase-2 (COX-2), 
and nitric oxide synthases (NOS). These studies showed CC had 
high expression levels of NF-κB, iNOS, and COX-2.1,6-8 How-
ever, most of these studies only assessed CC. Thus, we aimed to 
evaluate the expressions of various proinflammatory cytokines 
known to be associated with inflammatory bowel disease (IBD) 
in both CC and LC patients by immunohistochemical evalua-
tion.
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MATERIALS AND METHODS
1. Study populations/tissue specimens
All patients presented with chronic watery diarrhea for more 
than 4 weeks. Colonoscopy showed that all mucosa were nor-
mal or nearly normal. A colonic mucosal biopsy was done 
randomly at a point between the ascending colon and the rec-
tum, and the samples were immediately embedded in formalin. 
The LC and CC groups were each comprised of 6 patients with 
histological evidence for their respective diagnosis. The control 
group consisted of six patients with functional diarrhea neither 
any histological evidence of MC nor irritable bowel syndrome 
with diarrhea by Rome III criteria.
2. Diagnostic criteria of MC
LC was diagnosed on the basis of the histological findings of 
colonic mucosal biopsy specimens, including >20 intraepithelial 
lymphocytic infiltrations per 100 epithelial cells, inflammation 
in the lamina propria consisting of lymphocytes and plasma 
cells, and an absent subepithelial collagen layer or <10-μm 
subepithelial collagen layer. CC was diagnosed if the colonic 
mucosal biopsy specimen revealed a subepithelial collagen layer 
>10 μm.9-11 All biopsy specimens were evaluated by the same 
pathologist.
3. Immunohistochemistry 
Sections of formalin-fixed, paraffin-embedded tissue samples 
(4 to 5 μm) were dewaxed in xylene 3 times and thoroughly 
hydrated through a series of 100% ethanol twice, 70% ethanol 
once, and distilled H2O (dH2O) once. Sections were then sub-
jected to an antigen-retrieval step that consisted of a 10-minute 
microwave oven treatment in citrate buffer. After sections were 
cooled at room temperature, they were washed in phosphate-
buffered saline (PBS). Next, endogenous peroxidases were inac-
tivated in 3% hydrogen peroxide (H2O2)/methanol solutions, and 
the sections were washed in PBS 3 times. Sections were blocked 
in goat or rabbit serum and incubated with primary antibodies 
(all diluted 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) against COX-2, tumor necrosis factor-α (TNF-α), interleu-
kin-17 (IL-17), inducible nitric oxide synthase (iNOS), NF-κB, or 
IFN-γ overnight at 4oC. After removing the primary antibody by 
washing in PBS, the sections were incubated with an appropri-
ate biotin-conjugated secondary antibody (1:100) for 1 hour at 
room temperature. Next, the secondary antibody was removed 
by washing in PBS, and the avidin-biotin complex was ap-
plied for 30 minutes at room temperature. Diaminobenzidine 
was used to develop the color. After stopping the color reaction 
in dH2O, slides were incubated with hematoxylin for counter-
staining. The sections were then dehydrated in a series of 70%, 
80%, 90%, and 100% ethanol and cleared in xylene before they 
were mounted on microscope slides and cover-slipped. Images 
were acquired with a light microscope equipped with a digital 
camera.
4. Immunohistochemical quantification
There is no standardized method to evaluate immunohisto-
chemical quantification, although previous studies have defined 
their quantification procedures.1,8 In this study, positive cells 
were counted to quantify the immunohistochemical results. 
Locations were classified on the basis of whether the positive 
cells were epithelial or inflammatory, and staining ratios were 
quantitatively assessed on a scale from 0 to 2: 0, negative, i.e., 
<10% positive cells; 1, weakly positive, between 10% and 50% 
positive cells; and 2, strongly positive, >50% positive cells. After 
scoring each specimen, the total score was calculated as the sum 
of epithelial and inflammatory cell ratings.
5. Statistical analysis
SPSS version 22.0 (IBM Corp., Armonk, NY, USA) was used 
for all statistical analysis. Data are expressed as mean±standard 
deviation. Comparisons between two groups were performed 
with Mann-Whitney U tests. A p-value <0.05 was considered 
statistically significant.
RESULTS
Immunohistochemical stain of COX-2, IL-17, NF-κB, IFN-γ, 
iNOS, and TNF-α was performed using colonoscopic biopsy 
specimen of MC and control with quantification scoring of 
staining results (Table 1). 
COX-2, IL-17, IFN-γ, iNOS, and TNF-α were stained at cyto-
plasm of cells. NF-κB shows nuclear staining.
The expression of proinflammatory cytokines, including IL-17 
and IFN-γ were significantly increased in MC. The expression of 
COX-2 and NF-κB also increased significantly in MC. iNOS was 
expressed weakly on CC. TNF-α was not well expressed both 
Table 1. Comparison of the Quantification of Immunochemical Stain-
ing among the Groups
Control
MC
p-value* p-value†
LC CC
COX-2 1.67±0.52 2.00±1.79 4.00±0.00 0.045 0.022
IL-17 0.70±0.00 1.67±0.52 1.67±1.03 0.001 0.727
NF-κB 0.00±0.00 1.00±0.00 1.00±0.00 0.001 1.000
IFN-γ 1.33±1.03 3.33±0.52 3.00±0.89 0.002 0.484
iNOS 0.00±0.00 0.00±0.00 0.67±0.52 0.119 0.019
TNF-α 0.00±0.00 0.00±0.00 0.00±0.00 1.000 1.000
MC, microscopic colitis; LC, lymphocytic colitis; CC, collagenous coli-
tis; COX-2, cyclo-oxygenase-2; IL-17, interleukin-17; NF-κB, nuclear 
factor-κB; INF-γ, interferon-γ; iNOS, inducible nitric oxide synthase; 
TNF-α, tumor necrosis factor-α. 
*Comparison between control and MC groups; †Comparison between 
LC and CC groups.
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MC and control groups.
For COX-2, the immunohistochemical analysis yielded an 
epithelial cell quantity score of 1 and an inflammatory cell 
quantity score of 0, for a total score of 1 in the control group 
(Fig. 1A). In the LC group, the epithelial cell score was 1, the 
inflammatory cell score was 1, and the total score was 2 (Fig. 
1B). The epithelial and inflammatory cell scores were 2 and 2, 
respectively, for a total score of 4 in the CC group (Fig. 1C). 
Compared to the control group, there was significantly higher 
expression in CC and LC (p=0.045) (Fig. 1D). All other cytokines 
were quantified using the same protocol.
For IL-17, the epithelial and inflammatory cell scores were 
1 and 0 in the control group, respectively (Fig. 2A). In the LC 
group, both the epithelial and inflammatory cell scores were 1, 
for a total score of 2 (Fig. 2B). In the CC group, the epithelial 
cell score was 2, and the inflammatory cell score was 1, for total 
score of 3 (Fig. 2C). There was a statistically significant differ-
ence between control and MC groups (p=0.001) (Fig. 2D).
For NF-κB, the total score was 0 in the control group (Fig. 
3A), and expression was increased in the MC group. In the LC 
and CC group, only the epithelial cell count was increased, and 
the total score was 1 (Fig. 3B and C). The MC group showed in-
creased staining intensity compared the control group (p=0.001) 
(Fig. 3D).
Comparing between CC and LC, expression of IL-17, IFN-γ, 
and TNF-α was not significantly different. However, CC patients 
showed higher expression levels of COX-2 and iNOS than LC 
patients (Table 1) (p<0.05).
DISCUSSION
MC has two main entities: CC and LC. Microscopically, LC 
is characterized by a marked intraepithelial lymphocytosis, 
whereas CC exhibits increased subepithelial collagen deposition. 
Fig. 1. Immunohistochemical staining results for cyclo-oxygenase-2 (COX-2) (×400). Immunohistochemical analysis comparing the levels of 
COX-2 in control (A), lymphocytic colitis (LC) (B), and collagenous colitis (CC) (C). The positive expression of COX-2 was brown granules depos-
ited in the cytoplasm of the epithelial and inflammatory cells. The arrow indicates intraepithelial lymphocytosis in LC (B). The arrowhead shows 
the subepithelial collagen layer in CC (C). The graph shows the average quantity score of each group (D). The microscopic colitis group showed an 
increased quantity score compared to the control group (p=0.045). The CC group showed an increased quantity score compared to the LC group 
(p=0.022) (D).
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The pathogenesis of MC is not fully understood. Although the 
cytokine profile of IBD has been well studied, little is known 
about the inflammatory mediators involved in MC pathogenesis 
as relatively few studies have been performed. One report stated 
that MC patients predominantly had a Th1 type cytokine profile 
with marked increases in IFN-γ, IL 15, TNF-α, and iNOS.12 Other 
studies focused on abnormal immunomodulation in MC pa-
tients, including the evaluation of proinflammatory cytokines. 
Specifically, CC exhibited increased activities of NF-κB, iNOS, 
IFN-γ, and COX-2. Also, LC demonstrated increased IFN-γ.1,6-8
To our knowledge, there are few reports comparing cytokine 
profiles between the two MC disease entities. We performed im-
munohistochemical studies to compare proinflammatory cyto-
kine expression levels between CC and LC. Our analysis revealed 
that the expression levels of COX-2, IL-17, NF-κB, and IFN-γ 
were increased in the MC group compared with the control 
group. Also, COX-2 and iNOS expression levels were higher in 
CC than LC. 
COX-2, a prostaglandin synthase enzyme, is normally 
found at very low levels but is rapidly induced by a number 
of stimuli, including cytokines, growth factors, hormones, and 
carcinogens and is believed to be responsible for the produc-
tion of prostaglandins that mediate inflammation.8,13 A previous 
study described a clear relationship between IBD activity and 
COX-2 expression.14 COX-2 predominates under inflamma-
tory conditions and is also induced in cancer cells.15 Our study 
also showed COX-2 expression was strong in the MC groups 
and this was especially prominent for CC. This finding suggests 
that COX-2 and prostaglandin synthesis might be involved in 
MC pathogenesis. One previous study assessed CC samples and 
determined that only inflammatory cells in the lamina propria 
were COX-2 positive.8 Others have shown that COX-2 expres-
sion is also increased in epithelial cells in ulcerative colitis and 
Crohn’s disease.16,17 In our study, COX-2 expression levels were 
increased both in epithelial and inflammatory cells in the LC 
and CC groups, especially COX-2 expression in CC was signifi-
cantly stronger than LC (p=0.022). 
This is the first study of IL-17 expression in MC as far as we 
Fig. 2. Immunohistochemical staining results for interleukin-17 (IL-17) (×400). Immunohistochemical analysis comparing levels of IL-17 in con-
trol (A), lymphocytic colitis (LC) (B), and collagenous colitis (CC) (C). The positive expression of IL-17 is visualized as brown granules deposited 
in the cytoplasm of the epithelial and inflammatory cells. The arrow indicates intraepithelial lymphocytosis in LC (B). The arrowhead shows the 
subepithelial collagen layer in CC (C). The graph shows the average quantity score of each group (D). The microscopic colitis group showed an in-
creased quantity score compared with the control group (p=0.001). There were no significant differences between the LC and CC groups (p=0.727) (D).
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know. IL-17, which is produced by Th17 cells, serves an impor-
tant function in antimicrobial immunity at mucosal barriers by 
stimulating production of antimicrobial proteins by epithelial 
cells and neutrophil recruitment. However, because of its in-
flammatory nature, it is highly pathogenic in excess amounts 
and has been demonstrated to be a major player in IBD patho-
genesis.18 Also, an elevated level of IL-17 was found in patients 
with IBD.19 IL-17 plays a potential role in the amplification of 
intestinal inflammation by stimulating endothelial cells, myo-
fibroblasts, and epithelial cells.20,21 It also has important effects 
on intestinal permeability. One study reported that the mRNA 
level of IL-17 was increased in MC patients.18 In our study, we 
observed that IL-17 expression was increased in MC, both in 
epithelial cells and inflammatory cells, this result suggests that 
IL-17 also has an important role in MC pathogenesis, similar to 
IBD. Recently, an attempt to therapeutically inhibit IL-17 pro-
duction was performed in IBD patients. Vidofludimus, a novel 
small molecule inhibitor of dihydroorotate dehydrogenase, in-
hibited IL-17 production in activated lymphocytes and attenu-
ated various parameters of acute TNBS (2,4,6-trinitrobenzene-
sulfonic acid)-induced colitis in mice.22 Our study shows that IL-
17 regulation is another viable therapeutic option to treat MC.
NF-κB is a major transcription factor. NF-κB translocates into 
the nucleus where it binds to the promoter region of multiple 
genes with predominantly proinflammatory actions. In our 
study, the expression of NF-κB was significantly increased in 
both CC and LC. It suggested that proinflammatory cytokines 
was important for pathogenesis of MC.1
IFN-γ has a critical effect on intestinal permeability. In previ-
ous study, MC was likely to have a T helper cell type 1 cytokine 
profile including a predominance of IFN-γ, a lesser increase in 
TNF-α and increases in IL-15, iNOS and possibly IL-10. In our 
study, the expression of IFN-γ showed significantly increase in 
MC similar with that result.6
Fig. 3. Immunohistochemical staining results for nuclear factor-κB (NF-κB) (A, ×400; B, ×200; C, ×400). Immunohistochemical analysis compar-
ing the levels of NF-κB in control (A), lymphocytic colitis (LC) (B), and collagenous colitis (CC) (C). The positive expression of NF-κB is visualized 
as brown granules deposited in the nucleus of epithelial cells. The arrow indicates intraepithelial lymphocytosis in LC (B). The arrowhead shows 
the subepithelial collagen layer in CC (C).The graph shows the average quantity score of each group (D). The microscopic colitis group showed an 
increased quantity score compared with the control group (p=0.001). There were no significant differences between the LC and CC groups (p=1.000) 
(D).
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TNF-α expression in MC has only been investigated in two 
studies, both of which showed that it was increased in MC.12,18 
But, in our study TNF-α expression was very weak, less than 
10% stained cell in both epithelial and inflammatory cells in 
only CC. In LC, only one specimen expressed TNF-α on in-
flammatory cells in MC. TNF-α is the most well-known pro-
inflammatory mediator involved in the pathogenesis of IBD. It 
is released by activated macrophages and T cells and triggers 
a chain of cellular mediators that cause intestinal damage.23 
TNF-α has been reported to promote inflammation.24 For this 
reason, anti-TNF-α has been used in the last decade to treat 
IBD that is refractory to conventional treatment.25 But, accord-
ing to our study, the role of anti-TNF therapies in MC may be 
less valuable than IBD. Even though a few case reports have 
shown that anti-TNF therapies were effective in severe refrac-
tory MC.26,27 Further study will be necessary to confirm the role 
of anti-TNF-α in MC.
In this study, we verified the increased expression of proin-
flammatory cytokines such as IL-17, and IFN-γ in MC patients, 
suggesting that MC and IBD shares similar proinflammatory cy-
tokine profiles. These proinflammatory cytokines are known to 
be important in the pathogenesis of IBD patients. Because IL-17 
has been a key role in IBD, result of this study lead new insight 
of understanding pathogenesis of MC.
Our study has some limitations. One is that we used control 
group with functional diarrhea. Another is we could not confirm 
quantitative cytokine expression such as real-time polymerase 
chain reaction technique. Also we could not compare the cy-
tokine expression with clinical disease activity due to limited 
clinical information.
In conclusion, MC showed increased expression of proinflam-
matory cytokines including COX-2, IL-17, NF-κB, and IFN-γ 
compared to controls, which is similar with IBD. But contrary 
to IBD, TNF-α is not significantly expressed in both CC and LC. 
Also cytokine profiles between CC and LC didn’t show any sig-
nificant difference. COX-2 and iNOS showed relatively higher 
expression in CC than LC in immunohistochemical stain which 
will be confirmed by further study. 
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